Condition: Esophageal Cancer · Sponsor: Tianjin Medical University Cancer Institute and Hospital
A total of 120 patients with unresectable, locally advanced esophageal squamous cell carcinoma patients will be enrolled in this study and randomly divided into two groups. Arm A: After 2 cycles of induction adebrelimab plus chemotherapy, patients will be treated with concurrent chemoradiotherapy (50.4Gy/1.8Gy/28f), and adebrelimab will maintain to PD or for a maximum of 15 cycles. Arm B: Patients will be treated with concurrent chemoradiotherapy (50.4Gy/1.8Gy/28f) and adebrelimab will maintain to PD or for a maximum of 17 cycles. This study will compare the efficacy of immunotherapy in the induction and maintenance phases of radiotherapy, optimize more precise treatment plans, and potentially further increase the survival of ESCC patients.
This description comes directly from the study's public registry record.
Wencheng Zhang, MD · 02223340123 · wczhang@tmu.edu.cn
Always discuss trial participation with your own doctor first.
| Beijing Cancer Hospital | Beijing, Beijing Municipality, China | Recruiting |
| National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences | Beijing, Beijing Municipality, China | Recruiting |
| Henan Cancer Hospital | Zhengzhou, Hanan, China | Recruiting |
| Liaoning Cancer Hospital | Shenyang, Liaoning, China | Recruiting |
| Shanxi Cancer Hospital | Taiyuan, Shanxi, China | Recruiting |
| Sichuan Cancer Hospital | Chengdu, Sichuan, China | Recruiting |
| Tianjin Medical University Cancer Institute and Hospital | Tianjin, Tianjin Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07733830